These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37492235)

  • 1. COVID-19 vaccine-related adverse events following immunization in the WHO Western Pacific Region, 2021-2022.
    Amarasinghe A; Cho H; Katalbas ER; Takashima Y
    Western Pac Surveill Response J; 2023; 14(2):1-11. PubMed ID: 37492235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responding to COVID-19 vaccine-related safety events: WHO Western Pacific regional experience and lessons learned.
    Cho H; Amarasinghe A; Takashima Y
    Western Pac Surveill Response J; 2023; 14(2):1-6. PubMed ID: 37492237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of adverse events following immunisation in Australia, COVID-19 vaccines, 2021.
    Glover C; Deng L; Larter C; Brogan C; Richardson O; Huang YA; Kay E; Macartney K; Wood N
    Commun Dis Intell (2018); 2024 Jun; 48():. PubMed ID: 38926650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adverse events following immunization reported with COVID-19 vaccines in Burkina Faso: Analysis of spontaneous reports].
    Sawadogo R; Ouoba J; Ilboudo D; Tchoumbi E; Lankoandé-Haro S; Fofana S; Sombié I; Samadoulougou S; Kirakoya-Samadoulougou F
    Sante Publique; 2024 Feb; 35(6):149-159. PubMed ID: 38388395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services.
    Top KA; Chen RT; Levy O; Ozonoff A; Carleton B; Crawford NW; Creech CB; Kochhar S; Poland GA; Gutu K; Cutland CL
    Clin Infect Dis; 2022 Aug; 75(Suppl 1):S11-S17. PubMed ID: 35680552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imprecision in adverse event reports following immunization against HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of vaccine hesitancy and government policy.
    Inokuma Y; Kneller R
    Eur J Clin Pharmacol; 2023 Feb; 79(2):269-278. PubMed ID: 36527455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
    Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
    Front Immunol; 2021; 12():669010. PubMed ID: 34093567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
    Iguchi T; Umeda H; Kojima M; Kanno Y; Tanaka Y; Kinoshita N; Sato D
    Drug Saf; 2021 Nov; 44(11):1209-1214. PubMed ID: 34347278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature.
    Eslait-Olaciregui S; Llinás-Caballero K; Patiño-Manjarrés D; Urbina-Ariza T; Cediel-Becerra JF; Domínguez-Domínguez CA
    Ther Adv Drug Saf; 2023; 14():20420986231165674. PubMed ID: 37223456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging COVID-19 Vaccine Safety Monitoring in Ethiopia and Pakistan to Enhance System-Wide Safety Surveillance.
    Hagos AA; Sahile Z; Ahmed W; Phanouvong S
    Glob Health Sci Pract; 2024 Feb; 12(Suppl 1):. PubMed ID: 38216210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
    Kim MS; Jung SY; Ahn JG; Park SJ; Shoenfeld Y; Kronbichler A; Koyanagi A; Dragioti E; Tizaoui K; Hong SH; Jacob L; Salem JE; Yon DK; Lee SW; Ogino S; Kim H; Kim JH; Excler JL; Marks F; Clemens JD; Eisenhut M; Barnett Y; Butler L; Ilie CP; Shin EC; Il Shin J; Smith L
    J Med Virol; 2022 Mar; 94(3):1085-1095. PubMed ID: 34709664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India.
    Gandhi AP; Venkatesh U; Murali N
    Indian Heart J; 2023; 75(2):139-144. PubMed ID: 36863611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.
    Ferrara F; Mancaniello C; Varriale A; Sorrentino S; Zovi A; Nava E; Trama U; Boccellino M; Vitiello A
    Clin Drug Investig; 2022 Dec; 42(12):1065-1074. PubMed ID: 36274082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
    Ogar CK; Quick J; Gilbert HN; Vreman RA; Mantel-Teeuwisse AK; Mugunga JC
    Drug Saf; 2023 Apr; 46(4):357-370. PubMed ID: 36811813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Otorhinolaryngologic complications after COVID-19 vaccination, vaccine adverse event reporting system (VAERS).
    Shin J; Shim SR; Lee J; Ryu HS; Kim JY
    Front Public Health; 2023; 11():1338862. PubMed ID: 38269374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study.
    Serhan M; Psihogios A; Kabir N; Bota AB; Mithani SS; Smith DP; Zhu DT; Greyson D; Wilson S; Fell D; Top KA; Bettinger JA; Wilson K
    Hum Vaccin Immunother; 2024 Dec; 20(1):2293550. PubMed ID: 38374618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.